Segment and Geographic Area Information

12 Months Ended

Dec. 31, 2015

Segment and Geographic Area Information

Segment and Geographic Area Information

Note 15 Segment and Geographic Area Information

        AbbVie operates in one business segment—pharmaceutical products. Substantially all of AbbVie's net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues:

years ended December 31 (in millions)	2015		2014		2013
HUMIRA	$	14,012	$	12,543	$	10,659
IMBRUVICA		754		—		—
VIEKIRA		1,639		48		—
Creon		632		516		412
Synagis		740		835		827
Lupron		826		778		785
Synthroid		755		709		622
Kaletra		700		870		962
AndroGel		694		934		1,035
Sevoflurane		474		550		568
Duodopa		231		220		178
Dyslipidemia products		179		328		1,076
All other		1,223		1,629		1,666
Total net revenues	$	22,859	$	19,960	$	18,790

        Net revenues to external customers by geographic area, based on product shipment destination, were as follows:

years ended December 31 (in millions)	2015		2014		2013
United States	$	13,561	$	10,845	$	10,181
Germany		1,082		1,035		911
United Kingdom		688		722		606
Spain		618		534		543
Japan		599		581		625
France		597		584		540
Canada		551		551		538
Italy		452		432		404
Brazil		376		435		439
The Netherlands		334		345		332
All other countries		4,001		3,896		3,671
Total net revenues	$	22,859	$	19,960	$	18,790

        Long-lived assets include net property and equipment of $2.6 billion and $2.5 billion as of December 31, 2015 and 2014, of which $1.9 billion and $1.8 billion, respectively, was located in the United States and Puerto Rico and $513 million and $551 million, respectively, was located in Europe.